278 related articles for article (PubMed ID: 7566174)
1. A role for CD95 ligand in preventing graft rejection.
Bellgrau D; Gold D; Selawry H; Moore J; Franzusoff A; Duke RC
Nature; 1995 Oct; 377(6550):630-2. PubMed ID: 7566174
[TBL] [Abstract][Full Text] [Related]
2. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule.
Hori J; Joyce N; Streilein JW
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):443-52. PubMed ID: 10670474
[TBL] [Abstract][Full Text] [Related]
3. The role of Fas ligand as an effector molecule in corneal graft rejection.
Stuart PM; Yin X; Plambeck S; Pan F; Ferguson TA
Eur J Immunol; 2005 Sep; 35(9):2591-7. PubMed ID: 16114107
[TBL] [Abstract][Full Text] [Related]
4. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts.
Takeda Y; Gotoh M; Dono K; Nishihara M; Grochowiecki T; Kimura F; Yoshida T; Ohta Y; Ota H; Ohzato H; Umeshita K; Takeda T; Matsuura N; Sakon M; Kayagaki N; Yagita H; Okumura K; Miyasaka M; Monden M
Diabetologia; 1998 Mar; 41(3):315-21. PubMed ID: 9541172
[TBL] [Abstract][Full Text] [Related]
5. Evidence that retinal pigment epithelium functions as an immune-privileged tissue.
Wenkel H; Streilein JW
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3467-73. PubMed ID: 11006240
[TBL] [Abstract][Full Text] [Related]
6. Accelerated rejection of Fas ligand-expressing heart grafts.
Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
[TBL] [Abstract][Full Text] [Related]
7. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice.
Le Moine A; Surquin M; Demoor FX; Noël JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D
J Immunol; 1999 Oct; 163(7):3778-84. PubMed ID: 10490975
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
9. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
Stuart PM; Griffith TS; Usui N; Pepose J; Yu X; Ferguson TA
J Clin Invest; 1997 Feb; 99(3):396-402. PubMed ID: 9022072
[TBL] [Abstract][Full Text] [Related]
10. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
11. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice.
Baker MB; Podack ER; Levy RB
Biol Blood Marrow Transplant; 1995 Dec; 1(2):69-73. PubMed ID: 9118294
[TBL] [Abstract][Full Text] [Related]
12. Immune privilege and immunogenicity reside among different layers of the mouse cornea.
Hori J; Joyce NC; Streilein JW
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3032-42. PubMed ID: 10967061
[TBL] [Abstract][Full Text] [Related]
13. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.
Zhang HG; Su X; Liu D; Liu W; Yang P; Wang Z; Edwards CK; Bluethmann H; Mountz JD; Zhou T
J Immunol; 1999 Feb; 162(3):1423-30. PubMed ID: 9973398
[TBL] [Abstract][Full Text] [Related]
14. Critical role of Fas/Fas ligand interaction in CD28-independent pathway of allogeneic murine hepatocyte rejection.
Kawahara T; Kasai S; Yagita H; Sawa M; Kato K; Azuma M; Nakajima A; Okumura K; Futagawa S; Mito M
Hepatology; 1997 Oct; 26(4):944-8. PubMed ID: 9328317
[TBL] [Abstract][Full Text] [Related]
15. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.
Kusuhara M; Matsue H
Exp Dermatol; 2005 Apr; 14(4):273-80. PubMed ID: 15810885
[TBL] [Abstract][Full Text] [Related]
16. Deregulated c-Myc prematurely recruits both Type I and II CD95/Fas apoptotic pathways associated with terminal myeloid differentiation.
Amanullah A; Liebermann DA; Hoffman B
Oncogene; 2002 Feb; 21(10):1600-10. PubMed ID: 11896589
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway.
Ashany D; Savir A; Bhardwaj N; Elkon KB
J Immunol; 1999 Nov; 163(10):5303-11. PubMed ID: 10553053
[TBL] [Abstract][Full Text] [Related]
18. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
19. Fas/Fas ligand signaling during gestational T cell development.
Fleck M; Zhou T; Tatsuta T; Yang P; Wang Z; Mountz JD
J Immunol; 1998 Apr; 160(8):3766-75. PubMed ID: 9558079
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A
J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
